tbuckley/cabot-search huggingface dataset:
Long term results of ASTER study, a single Institution phase II trial of sequential chemotherapy (CT) for operable breast cancer (BC)
Authors: G. Mariani, G. Galli, S. Cavalieri, P. Valagussa, G. Bianchi, G. Capri, S. Cresta, L. Ferrari, S. Damian, M. Duca, F. de Braud, A. Moliterni
Journal: Annals of Oncology (2017)
Legionellosi associata ai viaggi in Europa nel 1999
Authors: C Joseph
Journal: Eurosurveillance (2001)

Fin dalla sua istituzione nel 1987, allo European Surveillance Scheme for Travel Associated Legionnaires’ Disease, il piu alto numero di casi fra i viaggiatori e stato notificato nel 1999. Questo dato riflette l'aumento delle attivita di sorveglianza e dell'uso di antigeni urinari per la ricerca del sierogruppo 1 di Legionella pneumophila. A complemento di questo programma intensivo di attivita di ricerca e divulgazione, in alcuni paesi si sommano anche le attivita dei tour operator che, dal 1996, anno in cui e entrata in vigore la Travel European Commission’s Package Directive, sono legalmente responsabili della salute e sicurezza dei loro clienti. Negli ultimi anni la collaborazione tra i gruppi di lavoro ha contribuito a istituire una buona attivita di sorveglianza e controllo nei luoghi frequentati dai viaggiatori.
P3.01-060 The Clinical Utility of ctDNA Gene Analysis in Lung Cancer
Authors: S. Geva, A. Belilovski Rozenblum, M. Ilouze, L. Roisman, E. Dudnik, A. Zer, T. Twito, A. Dvir, L. Soussan-Gutman, R. Lanman, N. Peled
Journal: Journal of Thoracic Oncology (2017)
Abstract 20348: Persistent Perinatal Cardiomyocyte Hyperplasia is an Early Response in Severe Familial Hypertrophic Cardiomyopathy
Authors: Emily T Farrell, Adrian C Grimes, Annie E Armstrong, Willem J de Lange, J Carter Ralphe
Journal: Circulation (2016)

Introduction:  Familial hypertrophic cardiomyopathy (HCM) affects ~1 in 200 individuals. The majority of HCM results from mutations in either β-myosin heavy chain ( MYH7 ) or cardiac myosin binding protein C ( MYBPC3 ). The pathway(s) by which these mutations lead to HCM are poorly understood, but it is largely accepted that myocyte hypertrophy is responsible for cardiac enlargement. Mice lacking MyBP-C (MyBP-C -/- ) are normal at birth but rapidly develop severe HCM by postnatal day (PND) 9. The mechanism underlying the rapid transition from a morphologically normal heart to enlargement is not known.   Methods & Results:  Microarray revealed upregulation of cell cycling genes in cMyBP-C -/-  vs. wild type (WT) mouse hearts at PND1 validated by qPCR. Immunohistochemistry revealed increased Ki-67, a cell cycling marker, in cMyBP-C -/-  hearts at PND1 and 2. By PND9, cell cycling was not different and “hypertrophic cardiomyopathy” became the most differentially regulated pathway between the WT and cMyBP-C -/-  hearts. Elevated cell cycling in cMyBP-C -/-  hearts was coincident with an increased heart weight (HW) to body weight (BW) ratio at PND2, which preceded cellular hypertrophy. Heterozygotes (cMyBP-C +/- ) showed intermediate transcriptional activation of cell cycling pathways with no evidence of hyperplasia at PND2, and no activation of hypertrophic pathways or hypertrophy at PND9.   Conclusions:  The elevation in cardiomyocyte proliferation in cMyBP-C -/-  vs WT mice, coincident with an increased HW to BW ratio, and occurring prior to the onset of cardiomyocyte hypertrophy, suggests that a higher number of cardiomyocytes in cMyBP-C -/-  hearts contributes to the hypertrophic phenotype. The graded differential gene expression in cMyBP-C +/-  vs cMyBP-C -/-  hearts may indicate a role for hyperplasia to impact the severity of HCM presentation. This may correlate with HCM in humans, where more severe manifestations occur in individuals homozygous for a single mutation, or in compound heterozygotes harboring two distinct mutations. In the immature heart, the interplay between hyperplasia and hypertrophy signaling could represent a novel early target for medical intervention.
EXTH-22. A NEW DESIGN FOR TRANSDUCER ARRAYS FOR THE DELIVERY OF TUMOR TREATING FIELDS
Authors: Ze’ev Bomzon, Yoram Wasserman, Michael Krinitsky, Michael Shtotland, Victor Kaikov, Eilon D Kirson
Journal: Neuro-Oncology (2017)

Tumor treating fields (TTFields) therapy is delivered to patients’ tumors via four transducer arrays placed on the patient’s scalp. When applying TTFields, the skin temperature below the arrays is monitored continuously to verify it does not exceed a safety threshold of 410C. The temperature sensing is performed using thermistors, positioned in the center of the ceramic insulator disks in the arrays. In the current array design, each of the four arrays is connected through a long wire to a Connector Array Device (CAD) where the temperature from all thermistors is read. Thus, in order to deliver TTFields using the current arrays, there is a need for four long cables running from the arrays to the CAD, which is located near the field generator and often clipped to the patient’s waist or carry bag. The use of four long wires makes the wiring coming off of a patient’s head less flexible and more visible. In addition, the presence of long wires attached to the arrays can make placement of the arrays on the head cumbersome. To overcome these challenges, we have designed a new generation of transducer arrays in which temperature measurements are performed using micro-processers located within connectors which connect to each array on the head. Therefore, placement of the arrays on the head can be performed without the need for individual wires to be connected to the CAD. Following individual array placement, the four arrays are connected via short, thin wires to a miniature hub, placed adjacent to or on the patient’s head. The miniature hub routes the communication from the arrays to the field generator using a single thin cable. This design is intended to significantly improve the ease-of-use and lower the visibility of the TTFields delivery arrays.
Early childhood linear growth faltering in low-income and middle-income countries as a whole-population condition: analysis of 179 Demographic and Health Surveys from 64 countries (1993–2015)
Authors: Daniel E Roth, Aditi Krishna, Michael Leung, Joy Shi, Diego G Bassani, Aluisio J D Barros
Journal: The Lancet Global Health (2017)

The causes of early childhood linear growth faltering (known as stunting) in low-income and middle-income countries remain inadequately understood. We aimed to determine if the progressive postnatal decline in mean height-for-age Z score (HAZ) in low-income and middle-income countries is driven by relatively slow growth of certain high-risk children versus faltering of the entire population.Distributions of HAZ (based on WHO growth standards) were analysed in 3-month age intervals from 0 to 36 months of age in 179 Demographic and Health Surveys from 64 low-income and middle-income countries (1993-2015). Mean, standard deviation (SD), fifth percentiles, and 95th percentiles of the HAZ distribution were estimated for each age interval in each survey. Associations between mean HAZ and SD, fifth percentile, and 95th percentile were estimated using multilevel linear models. Stratified analyses were performed in consideration of potential modifiers (world region, national income, sample size, year, or mean HAZ in the 0-3 month age band). We also used Monte Carlo simulations to model the effects of subgroup versus whole-population faltering on the HAZ distribution.Declines in mean HAZ from birth to 3 years of age were accompanied by declines in both the fifth and 95th percentiles, leading to nearly symmetrical narrowing of the HAZ distributions. Thus, children with relatively low HAZ were not more likely to have faltered than taller same-age peers. Inferences were unchanged in surveys regardless of world region, national income, sample size, year, or mean HAZ in the 0-3 month age band. Simulations showed that the narrowing of the HAZ distribution as mean HAZ declined could not be explained by faltering limited to a growth-restricted subgroup of children.In low-income and middle-income countries, declines in mean HAZ with age are due to a downward shift in the entire HAZ distribution, revealing that children across the HAZ spectrum experience slower growth compared to the international standard. Efforts to mitigate postnatal linear growth faltering in low-income and middle-income countries should prioritise action on community-level determinants of childhood HAZ trajectories.Bill & Melinda Gates Foundation.
Thrombin generation (TG) and D-dimer levels for the identification of cancer patients at higher VTE risk enrolled in the HYPERCAN study
Authors: C. Verzeroli, C. Giaccherini, M. Marchetti, G. Masci, L. Celio, B. Merelli, R. Sarmiento, S. Brevi, S. Gamba, V. Milesi, D. Raffaeli, L. Russo, C.J. Tartari, P. Malighetti, D. Spinelli, F. De Braud, R. Labianca, G. Gasparini, A. Santoro, A. Falanga
Journal: Annals of Oncology (2017)
Advance care planning for patients with chronic respiratory diseases: a systematic review of preferences and practices
Authors: Lea J Jabbarian, Marieke Zwakman, Agnes van der Heide, Marijke C Kars, Daisy J A Janssen, Johannes J van Delden, Judith A C Rietjens, Ida J Korfage
Journal: Thorax (2017)

Background Advance care planning (ACP) supports patients in identifying and documenting their preferences and timely discussing them with their relatives and healthcare professionals (HCPs). Since the British Thoracic Society encourages ACP in chronic respiratory disease, the objective was to systematically review ACP practice in chronic respiratory disease, attitudes of patients and HCPs and barriers and facilitators related to engagement in ACP. Methods We systematically searched 12 electronic databases for empirical studies on ACP in adults with chronic respiratory diseases. Identified studies underwent full review and data extraction. Results Of 2509 studies, 21 were eligible: 10 were quantitative studies. Although a majority of patients was interested in engaging in ACP, ACP was rarely carried out. Many HCPs acknowledged the importance of ACP but were hesitant to initiate it. Barriers to engagement in ACP were the complex disease course of patients with chronic respiratory diseases, HCPs’ concern of taking away patients’ hopes and lack of continuity of care. The identification of trigger points and training of HCPs on how to communicate sensitive topics were identified as facilitators to engagement in ACP. Conclusions In conclusion, ACP is surprisingly uncommon in chronic respiratory disease, possibly due to the complex disease course of chronic respiratory diseases and ambivalence of both patients and HCPs to engage in ACP. Providing patients with information about their disease can help meeting their needs. Additionally, support of HCPs through identification of trigger points, training and system-related changes can facilitate engagement in ACP. Systematic review registration number CRD42016039787.
Brotes epidémicos de gripe y de enfermedades pseudogripales en colegios de Inglaterra y Gales, 2005/06
Authors: H Zhao, C A Joseph, N Phin
Journal: Eurosurveillance (2007)

En Inglaterra y Gales, informes clinicos de atencion primaria revelaron que la actividad de la gripe en la temporada de 2005/06 solo supero el nivel basal durante cuatro semanas en febrero de 2006.
Targeted cancer therapy through antibody fragments-decorated nanomedicines
Authors: Abbas Alibakhshi, Fatemeh Abarghooi Kahaki, Shahrzad Ahangarzadeh, Hajar Yaghoobi, Fatemeh Yarian, Roghaye Arezumand, Javad Ranjbari, Ahad Mokhtarzadeh, Miguel de la Guardia
Journal: Journal of Controlled Release (2017)
Bojungbangamtang protects against cisplatin-induced toxicity via antioxidant activity
Authors: Yu Chang, Sook-Hyun Won, Hyo-Jung Lee, Eun-Ok Lee, Bum Shim, KyooSeok Ahn, Sung Kim
Journal: Cancer Research (2008)

5462   Cisplatin is a chemotherapeutic agent for the treatment of many human cancers. However, it frequently induces side effects such as nephrotoxicity and hepatotoxicity. Thus, in present study, we investigated whether Bojungbangamtang (BJBAT) reduces cisplatin-induced toxicity. BJBAT was daily administered for 15 days to the BALB/c mice subcutaneously inoculated with CT-26 colon cancer cells. Even though BJBAT and cisplatin effectively suppressed tumor growth, combination therapy of BJBAT and cisplatin was more effective than treatment of BJBAT or cisplatin alone. BJBAT significantly attenuated the serum levels of aspartate ammoniumtransferase and alanine ammoniumtransferase, blood urea nitrogen and creatinine in the mice with nephrotoxicity and hepatotoxicity induced by cisplatin. Futhermore, BJBAT significantly increased antioxidant enzymse such as superoxide dismutase (SOD), catalase and glutatione peroxidase (GSH-Px) in liver and kidney of cisplatin treated mice. These data strongly suggest that BJBAT may reduce nephrotoxicity and hepatotoxicity induced by cisplatin via antioxidant activity.
P1.01-018 Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression
Authors: A. Li, J. Yang, X. Zhang, J. Su, Q. Zhou, H. Chen, Z. Xie, H. Tu, W. Zhong, Z. Wang, C. Xu, Z. Chen, H. Yan, Y. Wu
Journal: Journal of Thoracic Oncology (2017)
Abstract 12940: Prognosis of Hemodialysis Patients With Severe Aortic Stenosis: Findings From the Contemporary Outcomes After Surgery and Medical Treatment in Patients With Severe Aortic Stenosis (CURRENT AS) Registry
Authors: Yuichi Kawase, Kazushige Kadota, Tomohiko Taniguchi, Takeshi Morimoto, Keiichiro Iwasaki, Akimune Kuwayama, Katsuya Miura, Masanobu Ohya, Takenobu Shimada, Hidewo Amano, Yasushi Fuku, Takeshi Maruo, Takeshi Kimura
Journal: Circulation (2016)

Background: Prognosis of hemodialysis (HD) patients with severe aortic stenosis (AS) remains unclear. Methods and Results: The CURRENT AS registry, a Japanese multicenter registry enrolled 3815 consecutive patients with severe AS. There were 1197 patients treated with the initial aortic valve replacement (AVR) strategy including surgical AVR and transcatheter aortic valve implantation and 2617 patients treated with the conservative strategy. The median follow-up duration after the index echocardiography was 1361 days, with a 90% follow-up at 2-year. HD patients accounted for 11% (405/3815 patients). The cumulative 5-year incidence of all-cause death (primary outcome measure) was significantly higher in HD patients than in non-HD patients in both the entire cohort and the initial AVR group (see Figure). Among HD patients, the initial AVR group as compared with the conservative group was associated with significantly lower cumulative 5-year incedences of all-cause death (see Figure) and sudden death (10.2% versus 31.7%, P&lt;0.001). Operative mortality rate at 30-day after AVR in HD patients was as high as 7.7% (10/131 patients). Conclusions: Being on HD indicates a grimmer prognosis in patients with severe AS, even when treated with the initial AVR strategy. The initial AVR strategy in HD patients was associated with high operative mortality risk, while it was associated with lower risk of death in long-term.
Nutritional Counseling with or without Systematic Use of Oral Nutritional Supplements in Head and Neck Cancer Patients Undergoing Radiotherapy
Authors: R. Caccialanza, P. Pedrazzoli, E. Cereda, S. Colombo, S. Cappello, A. Turri, M. Caraccia, V. Borioli, T. Monaco, I. Imarisio, C. Klersy, M. Benazzo, F. Corbella
Journal: Annals of Oncology (2017)
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
Authors: Dennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, Martin Sökler, Johannes C Hellmuth, Julia Meissner, Stephan Mathas, Max S Topp, Karolin Behringer, Wolfram Klapper, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann
Journal: The Lancet Oncology (2017)
RARE-25. A RETROSPECTIVE, SINGLE INSTITUTION STUDY OF CENTRAL NEUROCYTOMA (2004-2016): SURVIVAL, TREATMENT, AND SUPPORTIVE CARE
Authors: Margaret O Johnson, John P Kirkpatrick, Mallika P Weant, Anastasie Dunn-Pirio, Annick Desjardins, Dina Randazzo, Henry S Friedman, Katherine B Peters
Journal: Neuro-Oncology (2017)

Central neurocytoma (WHO grade II) represents 0.25-0.5% of all primary brain tumors. Given its rarity, the management is typically described in small case series. We describe our institutional experience in terms of survival, treatment, pathologic correlates, and supportive care interventions. This is an IRB-approved retrospective analysis of patients treated in our institution between 12/31/2004 and 10/12/2016. MRI and pathology reports were reviewed and confirmed the diagnosis in 9 patients. Two additional patients did not consent and were excluded. A total of 9 patients (2 females, 7 males) were identified with a mean age at diagnosis of 34.1 years (range 17-59, SD 15.0). All patients were alive at the time of analysis. 2 patients identified as Asian and 7 as White. The MiB labeling index (MiB) ranged from ≤2 to 20%. All underwent surgical resection and GTR was achieved in 5. Of those patients with GTR, 3 (MiB 3-5, 5 and 20%) received adjuvant radiotherapy (RT). A single patient with GTR and elevated MiB of 5% did not receive RT: this patient is progression-free at 38 months and is the only patient with a KPS of 100. There was a single case of recurrence in the patient with highest MiB (20%) treated with GTR, RT, and concurrent temozolomide. This patient is alive >10 years from diagnosis and 5.2 years after recurrence. A majority that received RT (n=6), were referred for neuropsychological evaluation with 4 patients requiring use of methylphenidate. This tumor has a favorable prognosis even with elevated MiB and in the setting of recurrence. Treatment for recurrence may include GTR and conformal RT with temozolomide. Further research on RT sparing treatments in the adjuvant setting is warranted. Referral for neuropsychological evaluation and symptomatic treatment with methylphenidate should be considered in patients who receive RT.
Brain metastases and ado-trastuzumab emtansine (TDM-1) treatment in HER2 positive metastatic patients: an Italian multicenter analysis
Authors: A. Fabi, D. Alesini, E. Valle, L. Carbognin, G. Arpino, D. Santini, F. Montemurro, M. Ciccarese, K. Cannita, I. Paris, L. Moscetti, M. De Laurentiis, A. Zambelli, N. La Verde, C. Nisticò, G. Ferretti, S. Gasparro, D. Giannarelli, F. Cognetti
Journal: Annals of Oncology (2017)
Mechanical or Biologic Prostheses for Aortic-Valve and Mitral-Valve Replacement
Authors: Andrew B. Goldstone, Peter Chiu, Michael Baiocchi, Bharathi Lingala, William L. Patrick, Michael P. Fischbein, Y. Joseph Woo
Journal: New England Journal of Medicine (2017)

In patients undergoing aortic-valve or mitral-valve replacement, either a mechanical or biologic prosthesis is used. Biologic prostheses have been increasingly favored despite limited evidence supporting this practice.We compared long-term mortality and rates of reoperation, stroke, and bleeding between inverse-probability-weighted cohorts of patients who underwent primary aortic-valve replacement or mitral-valve replacement with a mechanical or biologic prosthesis in California in the period from 1996 through 2013. Patients were stratified into different age groups on the basis of valve position (aortic vs. mitral valve).From 1996 through 2013, the use of biologic prostheses increased substantially for aortic-valve and mitral-valve replacement, from 11.5% to 51.6% for aortic-valve replacement and from 16.8% to 53.7% for mitral-valve replacement. Among patients who underwent aortic-valve replacement, receipt of a biologic prosthesis was associated with significantly higher 15-year mortality than receipt of a mechanical prosthesis among patients 45 to 54 years of age (30.6% vs. 26.4% at 15 years; hazard ratio, 1.23; 95% confidence interval [CI], 1.02 to 1.48; P=0.03) but not among patients 55 to 64 years of age. Among patients who underwent mitral-valve replacement, receipt of a biologic prosthesis was associated with significantly higher mortality than receipt of a mechanical prosthesis among patients 40 to 49 years of age (44.1% vs. 27.1%; hazard ratio, 1.88; 95% CI, 1.35 to 2.63; P<0.001) and among those 50 to 69 years of age (50.0% vs. 45.3%; hazard ratio, 1.16; 95% CI, 1.04 to 1.30; P=0.01). The incidence of reoperation was significantly higher among recipients of a biologic prosthesis than among recipients of a mechanical prosthesis. Patients who received mechanical valves had a higher cumulative incidence of bleeding and, in some age groups, stroke than did recipients of a biologic prosthesis.The long-term mortality benefit that was associated with a mechanical prosthesis, as compared with a biologic prosthesis, persisted until 70 years of age among patients undergoing mitral-valve replacement and until 55 years of age among those undergoing aortic-valve replacement. (Funded by the National Institutes of Health and the Agency for Healthcare Research and Quality.).
NIMG-95. RESTING STATE FUNCTIONAL MRI SHOWS DISTURBANCES IN FUNCTIONAL CONNECTIVITY IN THE NON-LESIONAL HEMISPHERE IN PATIENTS WITH HIGH-GRADE GLIOMA
Authors: Veit Stöcklein, Sophia Stoecklein, Birgit Ertl-Wagner, Niklas Thon, Friedrich-Wilhelm Kreth, Joerg-Christian Tonn, Hesheng Liu
Journal: Neuro-Oncology (2017)

Gliomas are malignant brain tumors that diffusely infiltrate the brain parenchyma. We hypothesized that this could lead to disturbances in neuronal connections and that the degree of damage to neuronal connections is correlated with the aggressiveness of the tumor as indicated by WHO grade. We used resting state functional MRI (rsfMRI) to test this hypothesis. 32 patients with de-novo gliomas (14 with WHO grade II tumors (=low grade gliomas; LGG), and 18 with WHO grade III and IV (=high grade gliomas; HGG)) were prospectively included and rsfMRI data were obtained. 13/14 LGG patients and 4/18 HGG patients had IDH-mutations. We developed a standardized score to evaluate the abnormality of functional connectivity in glioma patients by comparing each patient’s data to data obtained from 1000 healthy individuals. Abnormality was quantified at each voxel of the brain and then projected onto a standardized brain template, resulting in an individual abnormality map. Patients with HGGs had extensive disturbances in functional connectivity, which extended far beyond the solid tumor mass, invariably affecting the non-lesional hemisphere. In contrast, patients suffering from LGGs showed less damage to functional connectivity, which was mostly confined to the lesion-bearing hemisphere. In general, the degree of damage to functional connectivity was likely dominated by tumor histology, e.g. HGGs caused far more extensive damage to functional connectivity than LGGs. rsfMRI is a novel, non-invasive and easily implementable diagnostic tool in glioma patients which could discover characteristic disturbances in the non-lesional hemisphere of HGG patients. The correlation with tumor grading suggests that rsfMRI has great potential serve as an imaging biomarker for disease burden in glioma patients.
P1.13-007 Is Central Lung Tumor Location Really Predictive for Occult Mediastinal Nodal Disease in (Suspected) NSCLC Staged cN0 on PET-CT?
Authors: H. Decaluwe, J. Moons, W. De Wever, C. Deroose, A. Stanzi, L. Depypere, K. Nackaerts, J. Coolen, M. Lambrecht, D. De Ruysscher, J. Vansteenkiste, D. Van Raemdonck, P. De Leyn, C. Dooms
Journal: Journal of Thoracic Oncology (2017)
P3.02-059 T790M and C797S as Mechanisms of Acquired Resistance to Dacomitinib in Cell Models
Authors: Y. Kobayashi, T. Fujino, M. Nishino, S. Ohara, Y. Sesumi, M. Chiba, M. Shimoji, K. Tomizawa, T. Takemoto, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2017)